اعلان هااااااااااااااام


Translate

FibroGen and Astellas Announce Initiation of Phase 3 Trial of FG-4592/ASP1517 for Treatment of Anemia of Chronic Kidney Disease (pdf 66KB) (Astellas Pharma Inc)

Wednesday, December 12, 2012

WN.com - Health News
Latest headlines from WN Network
FibroGen and Astellas Announce Initiation of Phase 3 Trial of FG-4592/ASP1517 for Treatment of Anemia of Chronic Kidney Disease (pdf 66KB) (Astellas Pharma Inc)
Dec 12th 2012, 07:57

(Source: Astellas Pharma Inc) FibroGen and Astellas Announce Initiation of Phase 3 Trial of FG-4592/ASP1517 for Treatment of Anemia of Chronic Kidney Disease San Francisco and Tokyo, December 12, 2012 - FibroGen, Inc. ("FibroGen"), and Astellas Pharma Inc. (Tokyo:4503, "Astellas"), announced today the initiation of the first clinical study in the Phase 3 clinical development program of FG-4592/ASP1517, an orally administered small molecule, for treatment of anemia associated with chronic kidney disease ("CKD") in patients not on dialysis and on dialysis, to support approval in the U.S. and Europe. FG-4592/ASP1517 is an inhibitor of hypoxia-inducible factor (HIF) prolyl hydroxylase (a...
You are receiving this email because you subscribed to this feed at blogtrottr.com.

If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions

0 Responses to FibroGen and Astellas Announce Initiation of Phase 3 Trial of FG-4592/ASP1517 for Treatment of Anemia of Chronic Kidney Disease (pdf 66KB) (Astellas Pharma Inc)

Post a Comment